The results just have to pass a certain threshold. There is no "outstanding" vs "really good" debate in the FDA room in the approval of medicine. Your results are either statistically significant and pass the threshold in the identified markers or they are not. Your drug gets approved or it doesn't.
If this passes P3 (a repeat of P2 results) we win. If this fails P3 it will get hammered unmercilessly.
Share Price, page-152
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable